Welcome!

Agile Computing Authors: John Basso, Igor Drobiazko, Tim Hinds, Dan Sarel, Derek Weeks

News Feed Item

Rumors, News and Biotech Buzz Present Various Trade Opportunities

LOS ANGELES, CA -- (Marketwire) -- 01/18/13 -- A significant bunch of biotech deals were being discussed and closed at the recent biotech conferences in San Francisco.

Investors of all sizes were wagging their tongues about a number of upcoming developments and new opportunities in the market (bullish) following a busy week of presentations and simultaneous financial gatherings in the city by the bay. It looks to us like 2013 may be marked as a year of heavy biotech IPOs.

One particular privately held firm that may be looking to go public, caught our attention with their proposed once-a-week injectable basal insulin that is currently in preclinical development. AntriaBio's product looked highly intriguing as the formulation has been designed to release insulin slowly and uniformly over a period of seven days without an adverse initial burst of insulin. The subcutaneous injection would target a huge market of patients with type 1 and type 2 diabetes for the control of hyperglycemia. No official word yet on whether the firm is going to become publicly traded, but retail biotech investors seemed intrigued by the innovation which stemmed from nearby Menlo Park. Driving some of the excitement was the fact that the product has a history of development and venture capital with support from a top-notch management team behind it.

On the public side, we heard several rumors involving some of the stocks we've covered in this space, starting with two Israeli firms -- Pluristem Therapeutics Inc. (NASDAQ: PSTI) and Medgenics, Inc. We remain very bullish on both firms given important upcoming catalysts that some retail investors appear to have lost track of.

In addition to an almost certain Orphan Drug Designation that could be announced at any moment, Pluristem is also due to receive a very large multi-million dollar milestone payment tied to their progress of the development of PLX cells for the treatment of Pulmonary Hypertension from United Therapeutics.

Interestingly, there was also loud chatter about possible courtship activity involving Pluristem and a big pharma. Some mentioned both United Therapeutics (again) and Lonza as possible deal partners. Either would provide skeptics with further validation of Pluristem's various platforms which address several growing markets.

It's no secret that Lonza ($3.14B market cap) provides emerging and established innovators of novel therapeutics with expertise and advanced technologies while United Therapeutics ($2.65B market cap) already knows the firm, having signed an agreement with them in June of 2011. Under the terms of that agreement, United Therapeutics made an upfront payment of $7 million and Pluristem is eligible to receive regulatory milestone payments and other payments accumulating together with the upfront payment to a total of approximately $55 million and reimbursement of costs of its development and clinical activities. There are clearly a growing number of misguided shorts in the stock which run the risk of being intemperately squeezed at any moment. We would advise accumulating at these price levels given the discounted prices, very healthy cash position and multiple possibilities for strong catalyst reactions.

Speaking of catalysts, our favorite low-float biotech Medgenics is also rumored to be on the verge of announcing some important milestone developments in their quest to help solve the world-wide hepatitis epidemic. We are watching their progress on multiple fronts closely, as the stock tends to move up quickly on positive news. Medgenics' sustained production and delivery of interferon-alpha for the treatment of hepatitis using their INFRADURE™ technology has been drawing attention from experts in the field.

As we see across the biotech landscape, a number of competitors are scrambling and failing to fill the need for PEG-interferon and ribavirin therapy, the current standard known all too painfully to patients of the hepatitis virus. The race is on for an effective treatment that can improve patient compliance and reduce side effects.

A bet on Medgenics' own "miniature bio pump," which is impacted into the patient and continuously produces and releases the desired protein into the body, could pay off big -- especially when one considers that the technology has multiple applications in several billion dollar markets.

One stock we get a lot of e-mail about is the penny-priced, Phase III drug developer CEL-SCI Corp. (NYSE MKT: CVM). In December, they raised another round of gross proceeds, this time a total of approximately $10.5 million through a registered offering to institutional investors.

We've been seeing an increasing number of big block trades in that stock. It's logical to assume that some of those investors are expecting positive announcements involving further expansion of the firm's Phase III study of their immunotherapeutic agent Multikine® (Leukocyte Interleukin Injection), which is being developed as a potential first-line treatment for advanced primary head and neck cancer. Each time they have raised money, the firm has successfully and steadily been increasing the number of patients and clinical study sites with an eye on accelerating the approval process.

Still, other investors who know the company and follow the company may be taking positions as the already overly-aggressive flu season kicks off. We all know that this is a stock that tends to peak in the winter months because of the firm's activities in that space.

In a recent shareholder letter, CEO Geert Kersten stated that CEl-SCI's L.E.A.P.S. collaborative study with the National Institutes for Allergy and Infectious Diseases (NIAID) on pandemic flu was progressing well. "The testing conducted by NIAID with our L.E.A.P.S. compounds has shown significant promise in animal models of the disease and has been submitted for publication," said Kersten. "We believe that the data will potentially be very relevant when the next strain of drug resistant flu makes an appearance."

Finally, while it continues to trade sideways, we are seeing increased volume and attention being paid to Lpath, Inc. (NASDAQ: LPTN). That firm continues late-stage clinical testing and development of their product candidates iSONEP™ and ASONEP™ which target bioactive signaling lipids in order to treat diseases like Wet AMD, cancer, inflammation, fibrosis and a host of other indications. The stock appears to be getting close to eating through all of the over-hang left from the December 13th share offering which provided just under $12 million to the company.

We are paying particularly close attention to iSONEP™ which is being developed via a partnership with Pfizer (announced in December of 2010). That potential treatment for Wet AMD targets nearly 2 million patients in the U.S. alone and a positive outcome of that clinical trial could be enough to get Lpath taken out via a long rumored buy-out. We love the shares at these prices and the fact that the firm is now on a major exchange.

Disclosure: None

The full report including charts and technical analysis is available at:

http://www.biomedreports.com/20130118119619/rumors-news-and-biotech-buzz-present-various-trade-opportunities.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
You deployed your app with the Bluemix PaaS and it's gaining some serious traction, so it's time to make some tweaks. Did you design your application in a way that it can scale in the cloud? Were you even thinking about the cloud when you built the app? If not, chances are your app is going to break. Check out this webcast to learn various techniques for designing applications that will scale successfully in Bluemix, for the confidence you need to take your apps to the next level and beyond.
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, will discuss how research has demonstrated the value of Machine Learning in delivering next generation analytics to im...
This is not a small hotel event. It is also not a big vendor party where politicians and entertainers are more important than real content. This is Cloud Expo, the world's longest-running conference and exhibition focused on Cloud Computing and all that it entails. If you want serious presentations and valuable insight about Cloud Computing for three straight days, then register now for Cloud Expo.
IoT device adoption is growing at staggering rates, and with it comes opportunity for developers to meet consumer demand for an ever more connected world. Wireless communication is the key part of the encompassing components of any IoT device. Wireless connectivity enhances the device utility at the expense of ease of use and deployment challenges. Since connectivity is fundamental for IoT device development, engineers must understand how to overcome the hurdles inherent in incorporating multipl...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...